Detection of prostate cancer and its recurrence is challenging as it is a heterogeneous disease and methods such as PET imaging and measurement of biochemical response using prostate specific membrane ...

Getty Images Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer. The FDA has approved gallium 68 PSMA-11 (Ga 68 ...

Getty Images In a study, a positive PSMA PET/CT scan was associated with a significant 4.5-fold higher adjusted risk for disease progression. Positive results on PSMA PET/CT scans predict more ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) ...

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...

PSMA PET-CT is a diagnosit tool helping save men's lives with prostate cancer that has spread beyond the prostate gland Dr. David Samadi says that men with aggressive prostate cancer or a very high ...

Gene expression profiling of prostate tissue based on variable expression of 5-alpha reductase 2. This is an ASCO Meeting Abstract from the 2016 Genitourinary Cancers Symposium. This abstract does not ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

Please provide your email address to receive an email when new articles are posted on . A novel molecular imaging technique demonstrated higher diagnostic accuracy than conventional imaging among a ...

The FDA today approved Gallium 68 PSMA-11 as the first drug for PET imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer, according a press release from the ...